Manchester techbio Imperagen secures £5m for AI enzyme platform

Manchester-based techbio firm Imperagen has successfully closed a £5 million seed funding round, a significant step set to accelerate its AI-driven enzyme engineering platform. This investment is earmarked for advancing the development of novel enzymes, targeting a range of industrial and healthcare applications. The funding underscores a continued focus on leveraging artificial intelligence within the biotechnology sector to drive innovation.

The core of Imperagen's work lies in its AI-driven enzyme engineering platform. This sophisticated system is designed to facilitate the creation and optimisation of new enzymes, which are biological catalysts crucial for countless processes. By integrating artificial intelligence, the platform aims to streamline the discovery and development of these novel enzymes, potentially leading to more efficient and targeted solutions for complex biological challenges. The application of AI in this context is intended to enhance the precision and speed of enzyme design, moving beyond traditional methods.

The recently secured £5 million seed funding will be instrumental in pushing forward the capabilities of this platform. It is specifically allocated to accelerate the development pipeline, enabling Imperagen to expand its work on enzymes tailored for diverse industrial needs, such as manufacturing processes or sustainable chemistry. Concurrently, the funding will also support the exploration and creation of enzymes with potential applications in healthcare, where they could contribute to diagnostics, therapeutics, or drug discovery efforts.

What this means: This seed round positions Imperagen to substantially advance its proprietary technology. The capital injection is expected to enable faster progression from research to the practical application of its engineered enzymes, potentially impacting both industrial efficiency and medical innovation through its AI-driven approach.